Back
HFA Premium Access

Risk of safety events considered potential barriers to utilization of guideline-directed medical therapy among patients with worsening heart failure and ejection fraction 30% or lower

Session: Chronic heart failure - pharmacotherapy 1
Topic: Pharmacotherapy
Speaker: Professor S. Greene (Durham, US)
Event: Heart Failure 2023

Congress Presentation

Add to my library

Like

About the speaker

Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)
10 presentations
2 followers

6 more presentations in this session

Pharmacologic transition in the care of patients with heart failure with reduced ejection fraction - a real life analysis

Speaker: Doctor I. Cruz (Penafiel, PT)

Access
Abstract
Slides
Like
Thumbnail

Assessing the achievability of optimal therapy in patients with heart failure with reduced ejection fraction; a difficult task?

Speaker: Miss F. Bernier (Quebec, CA)

Access
Abstract
Slides
Like
Thumbnail

Clinical outcomes in patients with ischemic versus non-ischemic cardiomyopathy after angiotensin-neprilysin inhibition therapy

Speaker: Doctor C. Sabanoglu (Ankara, TR)

Access
Abstract
Slides
Like
Thumbnail

Five-year retrospective analysis of treatment efficacy effectiveness of sacubitril/valsartan in heart failure with reduced ejection fraction with end-stage renal disease

Speaker: Doctor B. Hsiao (Taipei, TW)

Access
Abstract
Slides
Like
Thumbnail

Is downtitration of diuretic therapy safe in patients with heart failure?

Speaker: Mr C. Geraeds (Maastricht, NL)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Chronic heart failure - pharmacotherapy 1

Speakers: Professor S. Greene, Doctor I. Cruz, Miss F. Bernier, Doctor C. Sabanoglu, Doctor B. Hsiao...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources